Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828347 | 0.80 | LMNA (0.33) | MEN1NPC1KMT2AATMHPGD | |
| SCHEMBL30228078 | 0.77 | MEN1 (0.30) | MEN1NPC1KMT2AATM | |
| SCHEMBL25109611 | 0.77 | MEN1 (0.30) | MEN1NPC1KMT2AATM | |
| SCHEMBL25107810 | 0.74 | KMT2A (0.38) | MEN1NPC1KMT2AATMHPGD | |
| SCHEMBL30295513 | 0.74 | — | — | |
| SCHEMBL24828553 | 0.74 | — | — | |
| SCHEMBL24828274 | 0.73 | ADORA2A (0.30) | — | |
| SCHEMBL25108402 | 0.73 | KMT2A (0.35) | MEN1NPC1KMT2AATMHPGD | |
| SCHEMBL24828574 | 0.72 | — | — | |
| SCHEMBL24828630 | 0.72 | HTT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4146626-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | MEN1 1607/4885NPC1 314/4885KMT2A 2069/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | MEN1 1170/4885NPC1 319/4885KMT2A 2154/4885 |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | MEN1 1170/4885NPC1 319/4885KMT2A 2154/4885 |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | MEN1 1607/4885NPC1 314/4885KMT2A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.